Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 9/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 9/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 3/20 | 1.00 |
| ▸ | CLK3 | P49761 | 3/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 1.00 |
| ▸ | CLK2 | P49760 | 2/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | DYRK2 | Q92630 | 1/20 | 1.00 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 3/20 | 0.70 |
| ▸ | PIM1 | P11309 | 2/20 | 0.70 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.70 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.70 |
| ▸ | MAP3K19 | Q56UN5 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5707661 | 1.00 | CLK1 (1.00) | CLK1DYRK1ACSNK1ECLK3DYRK1B | |
| SCHEMBL29772696 | 1.00 | CLK1 (1.00) | CLK1DYRK1ACSNK1ECLK3DYRK1B | |
| SCHEMBL5707659 | 1.00 | CLK1 (1.00) | CLK1DYRK1ACSNK1ECLK3DYRK1B | |
| SCHEMBL30754671 | 1.00 | CLK1 (1.00) | CLK1DYRK1ACSNK1ECLK3DYRK1B | |
| SCHEMBL16075921 | 0.86 | CLK1 (0.76) | CLK1DYRK1ACSNK1ECLK3DYRK1B | |
| SCHEMBL18166903 | 0.85 | CLK1 (0.74) | CLK1DYRK1ACSNK1ECLK3DYRK1B | |
| SCHEMBL4012671 | 0.85 | CLK1 (0.74) | CLK1DYRK1ACSNK1ECLK3DYRK1B | |
| SCHEMBL4013240 | 0.85 | CLK1 (0.74) | CLK1DYRK1ACSNK1ECLK3DYRK1B | |
| SCHEMBL4016027 | 0.85 | CLK1 (0.74) | CLK1DYRK1ACSNK1ECLK3DYRK1B | |
| SCHEMBL18166878 | 0.85 | CLK1 (0.74) | CLK1DYRK1ACSNK1ECLK3DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117500913-A | Method for producing multinucleated megakaryocyte having enhanced platelet production ability, method for producing platelets, method for producing platelet preparation, and method for producing blood preparation | 株式会社美加细胞 | 2024-02-02 | — | — | CN | disclosed |
| US-11788064-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-10-17 | — | — | US | disclosed |
| US-11788064-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2022255411-A1 | METHOD FOR ENHANCING INNATE IMMUNE RESPONSE | 国立大学法人京都大学 | 2022-12-08 | — | — | WO | disclosed |
| US-20170281607-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES | UNIV LIMERICK (IE) | 2017-10-05 | — | — | US | disclosed |
| US-20170281607-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES | UNIV LIMERICK (IE) | 2017-10-05 | — | — | US | disclosed |
| US-20170281607-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES | UNIV LIMERICK (IE) | 2017-10-05 | — | — | US | disclosed |
| US-9446044-B2 | DYRK1 inhibitors and uses thereof | DIAXONHIT (FR) | 2016-09-20 | — | — | US | disclosed |
| US-9446044-B2 | DYRK1 inhibitors and uses thereof | DIAXONHIT (FR) | 2016-09-20 | — | — | US | disclosed |
| EP-2744797-B1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2015-09-09 | — | — | EP | disclosed |
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2014-09-18 | — | — | US | disclosed |
| WO-2013026806-A1 | DYRK1 INHIBITORS AND USES THEREOF | EXONHIT SA (FR) | 2013-02-28 | — | — | WO | disclosed |
| WO-2009085226-A2 | INHIBITORS OF CDC2-LIKE KINASES (CLKS) AND METHODS OF USE THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009085226-A2 | INHIBITORS OF CDC2-LIKE KINASES (CLKS) AND METHODS OF USE THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11788064-B2 | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition | IAPP, GLP1R, GPR119 | CLK1 35/4885DYRK1A 5/4885CSNK1E 42/4885 |
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | CLK1 83/4885DYRK1A 1/4885CSNK1E 94/4885 |
| US-20170281607-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES | IAPP, GPR119, INSR | CLK1 370/4885DYRK1A 1775/4885CSNK1E 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.